Drug Profile

TEV 325

Alternative Names: BD-9; Dual specific antibody - Biolojic Design; TEV-325; TEV-56308

Latest Information Update: 07 Apr 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Biolojic Design
Class Anti-inflammatories; Antiasthmatics; Bispecific antibodies; Skin disorder therapies
Mechanism of Action Interleukin 13 inhibitors; Thymic stromal lymphopoietin inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Asthma; Atopic dermatitis

Most Recent Events

25 Mar 2026 Biolojic Design and Teva Pharmaceutical Industries plan a clinical trial for Asthma and Atopic dermatitis (Parenteral), in 2027
14 Dec 2023 BD 9 licensed to Teva Pharmaceutical Industries worldwide
14 Dec 2023 Preclinical trials in Atopic dermatitis in Israel (Parenteral) before December 2023

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com